Protuoso Biosciences announced the close of an oversubscribed $9.5 million seed financing round to advance its AI-driven protein synthetic biology platform and multifunctional biologics pipeline targeting cardiometabolic, oncology, and autoimmune diseases.
The financing round was led by Taya Venture and Darwin Ventures, with participation from NSG Ventures, SEEDS, and other investors. The company said the proceeds will support the development of its multifunctional protein engineering platform, along with the expansion of its therapeutic pipeline.
Protuoso Biosciences is developing a therapeutic-agnostic hub-and-spoke business model in which its core protein engineering platform acts as the central hub for generating multiple therapeutic candidates across disease categories with high unmet medical need. Programs are then advanced through focused “spokes,” enabling parallel development and early business development discussions at the asset level.
At the center of the company’s platform are its MUXBODIES, fully recombinant fusion proteins engineered to combine different protein modalities, including antibodies, cytokines, peptides, and signaling modules, into a single therapeutic. The biologics are designed to engage multiple biological mechanisms simultaneously and to support coordinated, multifunctional activities, such as agonist and antagonist behavior, programmable protein logic, and optimized pharmacokinetics.
The company said the modular “mix-and-match” MUXBODY architecture enables the engineering of multispecific and multifunctional biologics for complex diseases where single-pathway targeting has historically yielded limited efficacy and durability.
Protuoso’s platform combines computational protein design, massively parallel synthetic biology, and AI-enabled modular protein engineering to optimize multi-domain fusion proteins. The company believes this approach can support the development of a new class of biologics capable of addressing complex disease biology beyond traditional single-mechanism therapies.
The company currently has programs focused on cardiometabolic diseases and solid tumors and is expanding into autoimmune diseases. In cardiometabolic diseases, Protuoso is developing multifunctional biologics targeting both systemic obesity and downstream organ-related diseases. In oncology, the company is advancing next-generation armored immune-cell-engager programs designed to address immune exhaustion and durability challenges in solid tumors.
Protuoso said its hub-and-spoke structure is designed to support both internal drug development and external transactions, enabling individual programs to be partnered, spun out, or independently advanced while maintaining capital efficiency and creating multiple pipeline value inflection points.
KEY QUOTES:
“Many of the largest disease areas such as obesity, cardiovascular diseases, cancer, and autoimmune diseases are fundamentally driven by interconnected biology, but most drugs still act on a single pathway. Our platform gives us the ability to engineer multiple modalities into a single molecule to target a variety of disease mechanisms. Our flexible hub-and-spoke company structure lets us efficiently translate our diverse MUXBODY programs into the clinic.”
Willie Xiang, Co-Founder, President and COO, Protuoso Biosciences
“Most biologics today are limited to a single mechanism or modality, as combining multiple functions into one molecule has historically been very complex to engineer. As functionality increases, design complexity grows exponentially, which has constrained innovation. Advancements in synthetic biology, AI, and protein design have now enabled us to build a platform that reduces this complexity and achieves scalable development of multifunctional biologics. We believe this approach will unlock more effective therapies for complex diseases and expand the range of what biologics can achieve.”
Tim Lu, Ph.D., Co-Founder and Chairman, Protuoso Biosciences
“We’ve invested in leading healthcare funds and global biotech companies, and Protuoso reflects the qualities we look for in an early-stage life sciences platform. The combination of a transformative platform technology, an experienced team with a proven track record of advancing multiple high-value assets into the clinic, and a clear path to clinical development forms a strong foundation for long-term value creation.”
Christopher Shen, General Manager, Taya Venture
“Protuoso is being built with the rigor and discipline of successful biotech organizations. The company’s capital-efficient business model, combined with deep platform innovation and R&D execution, uniquely positions the company to address profound unmet needs across cardiometabolic, oncology, and autoimmune disease.”
Laura Brege, Senior Advisor, Protuoso and BridgeBio
